Dyadic Reports 2022 Year End Results and Recent Company Prog

Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19

Related Keywords

South Africa , United States , India , Oslo , Norway , American , Mark Emalfarb , National Institute For Innovation , Rubic One Health , Janssen Pharmaceutical Companies Of Johnson , African Health Products Regulatory Authority , Foreign Currency Exchange , Global Food Ingredient Company , Dyadic International , Dyadic International Inc , Phibro Animal Health Corporation , Securities Exchange , Third Party , Phibro Animal Health , University Of Oslo , Exchange Commission , Exchange Commission On , Company Progress , Janssen Biotech Inc , Abic Biological Laboratories Ltd , Human Health , Animal Health , First In Human Phase , Chief Executive Officer , Hazelton Dyadic , Chief Business Officer , One Health , Epygen Biotech , Collaboration Agreement , Janssen Biotech , Janssen Pharmaceutical Companies , National Institute , Manufacturing Biopharmaceuticals , White House , American Rescue Plan , Serum Albumin , Bird Flu , Abic Biological Laboratories , Abic Agreement , Reviewed Journals , Corporate Website , Currency Exchange , Non Operating Items , Toll Free , Investor Relations , Securities Act , Securities Exchange Act , Ended December , Consolidated Financial Statements , Annual Report ,